UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026105
Receipt number R000029348
Scientific Title Treatment with anti-histamine ointment on eyelids for allergic conjunctivitis
Date of disclosure of the study information 2017/02/13
Last modified on 2019/07/18 20:39:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Treatment with anti-histamine ointment on eyelids for allergic conjunctivitis

Acronym

Anti-histamine ointment on eyelids for allergic conjunctivitis

Scientific Title

Treatment with anti-histamine ointment on eyelids for allergic conjunctivitis

Scientific Title:Acronym

Anti-histamine ointment on eyelids for allergic conjunctivitis

Region

Japan


Condition

Condition

allergic conjunctivitis

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of trans-dermal application of diphenhydramine ointment over the eyelids in the patients with allergic conjunctivitis.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase I,II


Assessment

Primary outcomes

Subjective effectiveness by the patients, 2 weeks after the introduction of the therapy.

Key secondary outcomes

adverse effects (vision test, intraocular pressure)
objective effectiveness judged by clinicians.
QOL.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Diphenhydramine ointment of 1/4 Finger tip units will be applied to each eyelid twice a day for 2 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

# Patients with allergic conjunctivitis.
# Persistent symptoms despite the conventional treatment such as anti-histamine topically or orally given.
# No change of drugs 4 weeks prior to the enrollment.

Key exclusion criteria

# Those with underlying dermal disease of eyelids such as atopic dermatitis.
# Those with newly introdeced anti-allergic, anti-histamine, steroids.
# Patients with pregnancy and lactation.
# Those whom the attending clinicians regard to be unsuitable to the enrollment to the study.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Mitsuhiro
Middle name
Last name Kamimura

Organization

National Hospital Organization Disaster Medical Center

Division name

Department of pulmonology

Zip code

190-0014

Address

Midorimachi 3256, Tachikawa, Tokyo

TEL

042-526-5511

Email

tdmckamimura@yahoo.co.jp


Public contact

Name of contact person

1st name Mitsuhiro
Middle name
Last name Kamimura

Organization

National Hospital Organization Disaster Medical Center

Division name

Department of pulmonology

Zip code

190-0014

Address

Midorimachi 3256, Tachikawa, Tokyo

TEL

042-526-5511

Homepage URL


Email

tdmckamimura@yahoo.co.jp


Sponsor or person

Institute

National Hospital Organization Disaster Medical Center
Department of pulmonology

Institute

Department

Personal name



Funding Source

Organization

National Hospital Organization Disaster Medical Center
Department of pulmonology

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Faculty of Pharmaceutical Sciences, Josai University

Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Hospital Organization Disaster Medical Center

Address

Midorimachi 3256, Tachikawa, Tokyo

Tel

042-526-5511

Email

tdmckamimura@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立病院機構災害医療センター


Other administrative information

Date of disclosure of the study information

2017 Year 02 Month 13 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 12 Month 20 Day

Date of IRB

2016 Year 12 Month 20 Day

Anticipated trial start date

2017 Year 01 Month 20 Day

Last follow-up date

2017 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete

2018 Year 06 Month 23 Day

Date analysis concluded

2018 Year 06 Month 23 Day


Other

Other related information



Management information

Registered date

2017 Year 02 Month 12 Day

Last modified on

2019 Year 07 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029348


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name